Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 2Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

tusamitamab ravtansine 2Ramucirumab 2Docetaxel 2telomerase reverse transcriptase p572Y, human 1pembrolizumab 1necitumumab 1Paclitaxel 1LY3023414 1Gemcitabine 1Erlotinib Hydrochloride 1Data Collection 1Carboplatin 1Bevacizumab 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-small Cell Lung Cancer Metastatic × necitumumab × Clear all
NCT02443337 2020-12-09

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Eli Lilly and Company

Phase 2 Terminated
31 enrolled 14 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡